Tonix Pharmaceuticals (NASDAQ:TNXP) has bolstered TONMYA coverage to roughly 145M lives with payer deals adding ~9M Medicare lives and Part D from 2027, while a Journal of Virology study identified murine models and lower virulence of 2022 mpox clade IIb—supporting testing of TNX-801.
Previous Week Recap
- Tonix Expands Medicare Coverage: Tonix (TNXP) secured payer deals adding ~9M Medicare lives and Medicare Part D coverage from Jan 1, 2027, raising total TONMYA coverage to about 145M lives (~46% of 314M).
- Study Finds Mpox Reduced Virulence: Tonix (TNXP) says a Journal of Virology study found 2022 mpox clade IIb up to 100,000× less virulent than IIa in mice and identified three murine models to test countermeasures, including TNX-801
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.